DNV-001

N/A

Report date: 2026/02/10 20:00:22
NME

Base Information

Drug NameDNV-001
Drug Alias NameDNV001DNV-001
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionProprotein convertase subtilisin kexin type 9 modulators
TargetsProprotein convertase subtilisin kexin type 9
Therapy Area/IndicationsHypercholesterolemiaDyslipidemiasHyperlipidemia, Familial Combined
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesHangzhou Dingle New Biotechnology Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesHangzhou Dingle New Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsHypercholesterolemiaDyslipidemiasHyperlipidemia, Familial Combined
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A